|
Chemoradiotherapy in malignant glioma: standard of care and future directions. |
50.00% |
|
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities |
50.00% |
|
Inhibition of angiogenesis by non-toxic doses of temozolomide. |
50.00% |
|
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. |
50.00% |
|
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary |
50.00% |
|
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. |
50.00% |
|
Roles of sildenafil in enhancing drug sensitivity in cancer. |
50.00% |
|
Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in |
50.00% |
|
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report) |
50.00% |
|
Case report of a pituitary macroadenoma treated with artemether. |
50.00% |
|
Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome: Methodische Mängel |
50.00% |
|
Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase |
50.00% |
|
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. |
50.00% |
|
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. |
50.00% |
|
WITHDRAWN: Ovarian ablation for early breast cancer. |
50.00% |
|
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. |
50.00% |
|
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. |
50.00% |
|
Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata. |
50.00% |
|
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) |
50.00% |
|
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. |
50.00% |
|
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and |
50.00% |
|
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non |
50.00% |
|
Results of Ukrain monotherapy of prostate cancer |
50.00% |
|
Glioblastoma Multiforme |
50.00% |
|
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. |
50.00% |
|
Carbon-ion treatment |
50.00% |
|
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe |
50.00% |
|
Role of everolimus in the treatment of renal cell carcinoma. |
50.00% |
|
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. |
50.00% |
|
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. |
50.00% |
|
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. |
50.00% |
|
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal |
50.00% |
|
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom |
50.00% |
|
An RF hyperthermia electrode which generates no edge effect. |
50.00% |
|
Cancer Prevention |
50.00% |
|
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp |
50.00% |
|
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit |
50.00% |
|
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. |
50.00% |
|
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer |
50.00% |
|
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? |
50.00% |
|
Some pharmacological properties of prolonged administration of Ukrain in rodents |
50.00% |
|
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 |
50.00% |
|
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... |
50.00% |
|
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. |
50.00% |
|
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. |
50.00% |
|
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line |
50.00% |
|
Tumoral angiogenesis: review of the literature. |
50.00% |
|
Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin.... |
50.00% |
|
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study |
50.00% |
|
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother |
50.00% |
|
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera |
50.00% |
|
Novel anti-angiogenic therapies for malignant gliomas. |
50.00% |
|
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. |
50.00% |
|
The story of the cancer medicine Ukrain and Wassil Nowicky |
55.00% |
|
Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice |
55.00% |
|
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid |
55.00% |
|
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. |
55.00% |
|
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). |
55.00% |
|
Pycnogenol may alleviate adverse effects in oncologic treatment. |
60.00% |
|
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and |
60.00% |
|
Systematic review of the treatment of cancer-associated anorexia and weight loss. |
60.00% |
|
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. |
60.00% |
|
Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angio.. |
60.00% |
|
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. |
60.00% |
|
Unconventional anticancer agents: a systematic review of clinical trials. |
60.00% |
|
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare |
60.00% |
|
Beta-solamarine: tumor inhibitor isolated from Solanum dulcamara. |
60.00% |
|
Preliminary studies on the effect of Ukrain on the immunological response in patients with malignant tumours. |
60.00% |
|
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of |
60.00% |
|
Focal therapy for prostate cancer: revolution or evolution? |
60.00% |
|
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. |
60.00% |
|
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. |
60.00% |
|
Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. |
60.00% |
|
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........ |
60.00% |
|
Strong synergy of heat and modulated electromagnetic field in tumor cell killing. |
60.00% |
|
Complete remission of psoriasis following bevacizumab therapy for colon cancer. |
60.00% |
|
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel |
60.00% |
|
Radiomodification effects of Ukrain, a cytostatic and immunomodulating drug, on intracellular glucocorticoid reception during sh |
60.00% |
|
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. |
60.00% |
|
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m |
60.00% |
|
Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate |
60.00% |
|
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. |
60.00% |
|
Boswellia |
60.00% |
|
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... |
60.00% |
|
Survivin and pancreatic cancer. |
60.00% |
|
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. |
60.00% |
|
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer |
60.00% |
|
Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells |
60.00% |
|
Serum calcium and the risk of prostate cancer. |
60.00% |
|
Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. |
60.00% |
|
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. |
60.00% |
|
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect |
60.00% |
|
A case of metronomic chemotherapy as an alternative cancer therapy for palliation |
60.00% |
|
Does the Ukrain preparation protect mice against lethal doses of bacteria? |
60.00% |
|
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky |
60.00% |
|
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
60.00% |
|
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi |
60.00% |
|
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. |
60.00% |
|
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. |
60.00% |
|
Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marr |
60.00% |
